Myocyte-specific enhancer factor 2D promotes tumorigenesis and progression in tongue squamous cell carcinoma.
Tongue squamous cell carcinoma (TSCC)
myocyte-specific enhancer factor 2 (MEF2D)
proliferation
tumorigenesis
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
10
2019
accepted:
25
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Tongue squamous cell carcinoma (TSCC) ranks as one of the most common cancers worldwide and has a poor prognosis. Myocyte-specific enhancer factor 2 (MEF2D) has recently been considered as a novel factor involved in cancer development. In the present study, the function and underlying mechanism of MEF2D in TSCC were investigated. The levels of MEF2D mRNA and protein were determined in human TSCC samples by RT-qPCR and western blot, respectively. The interaction between MEF2D expression and clinicopathologic features was evaluated by IHC and analysis of clinical information. MEF2D-mediated effects on proliferation, migration, and invasion were explored in TSCC cells after transfection with MEF2D-siRNA. The results showed higher expression of MEF2D at both the mRNA and protein levels in TSCC carcinoma tissues than in paracarcinoma tissues. Furthermore, high expression of MEF2D was positively correlated with tumor differentiation and lymphatic metastasis. MEF2D knocked down TSCCA cells also had reduced proliferative, migratory, and invasive abilities compared to those of control cells. Together, these data confirmed that knockdown of MEF2D might suppress the growth and metastasis of TSCC, which further indicated that MEF2D might serve as a therapeutic target for TSCC treatment.
Types de publication
Journal Article
Langues
eng
Pagination
934-943Informations de copyright
IJCEP Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Head Neck. 2016 Apr;38 Suppl 1:E859-66
pubmed: 25917601
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1873-1882
pubmed: 29518496
Onco Targets Ther. 2017 Aug 29;10:4193-4203
pubmed: 28919775
Oral Oncol. 2018 Dec;87:43-48
pubmed: 30527242
Curr Opin Cell Biol. 1999 Dec;11(6):683-8
pubmed: 10600704
Oral Oncol. 2018 Dec;87:1-7
pubmed: 30527223
Biochem Biophys Res Commun. 2015 Oct 23;466(3):327-32
pubmed: 26362179
J Am Dent Assoc. 2001 Nov;132 Suppl:7S-11S
pubmed: 11803655
J Oral Maxillofac Surg. 2019 Jan;77(1):184-194
pubmed: 30218654
Oncol Rep. 2015 Feb;33(2):974-80
pubmed: 25483152
Tumori. 2018 Jun;104(3):221-231
pubmed: 29714661
J Biol Chem. 2015 Jan 2;290(1):310-24
pubmed: 25404735
J Cancer Educ. 2018 Aug;33(4):865-869
pubmed: 28220285
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240
pubmed: 29355614
Oncogene. 2014 Jan 23;33(4):403-10
pubmed: 23435431
Indian J Surg Oncol. 2018 Dec;9(4):501-504
pubmed: 30538379
FEBS Lett. 2000 Jul 14;477(1-2):135-40
pubmed: 10899324
J Calif Dent Assoc. 2013 Nov;41(11):831-8
pubmed: 24341135
J Hematol Oncol. 2015 Oct 20;8:115
pubmed: 26487643
Aging (Albany NY). 2012 Feb;4(2):133-43
pubmed: 22361433
Int J Mol Med. 2018 Sep;42(3):1418-1426
pubmed: 29956740
Biomed Pharmacother. 2017 Aug;92:913-918
pubmed: 28605875
J Biol Chem. 1998 Dec 25;273(52):34904-10
pubmed: 9857019
Laryngoscope. 2016 Oct;126(10):2252-6
pubmed: 27010175
Biochem Biophys Res Commun. 2017 Nov 4;493(1):833-839
pubmed: 28821430
J Cancer Res Clin Oncol. 2008 Jan;134(1):83-91
pubmed: 17611778
Cancer Cell. 2017 Apr 10;31(4):591-606.e6
pubmed: 28344040
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Oncogene. 2015 Jul 30;34(31):4089-97
pubmed: 25328135
Acta Neuropathol. 2004 Sep;108(3):241-9
pubmed: 15221330
J Clin Med. 2018 Dec 01;7(12):
pubmed: 30513726
Mol Cell Biol. 2007 Dec;27(23):8143-51
pubmed: 17875930
Zhonghua Kou Qiang Yi Xue Za Zhi. 2018 Sep 9;53(9):640-644
pubmed: 30196628